Plus Therapeutics, Inc. (NASDAQ:PSTV) Sees Significant Increase in Short Interest

Plus Therapeutics, Inc. (NASDAQ:PSTV) was the target of a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 205,300 shares, an increase of 19.8% from the May 31st total of 171,300 shares. Approximately 3.7% of the shares of the company are sold short. Based on an average daily volume of 75,300 shares, the days-to-cover ratio is presently 2.7 days.

Insider Buying and Selling at Plus Therapeutics

In related news, CEO Marc H. Hedrick bought 12,255 shares of the stock in a transaction dated Wednesday, May 8th. The shares were purchased at an average price of $2.04 per share, for a total transaction of $25,000.20. Following the completion of the purchase, the chief executive officer now directly owns 12,425 shares of the company’s stock, valued at $25,347. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have bought 26,961 shares of company stock worth $55,000. 2.32% of the stock is currently owned by insiders.

Plus Therapeutics Stock Up 1.1 %

Shares of PSTV traded up $0.02 during mid-day trading on Tuesday, reaching $1.52. The company had a trading volume of 15,341 shares, compared to its average volume of 54,331. Plus Therapeutics has a 52-week low of $0.97 and a 52-week high of $3.21. The stock has a market capitalization of $8.65 million, a P/E ratio of -0.50 and a beta of 0.54. The stock has a 50 day moving average of $2.01 and a two-hundred day moving average of $1.94.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($0.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.34. The company had revenue of $1.68 million during the quarter. Plus Therapeutics had a negative return on equity of 805.57% and a negative net margin of 193.49%. During the same period in the previous year, the company posted ($2.10) EPS.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.